Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Thrombocytosis × ruxolitinib × Clear all

Phase

Status

Completed 2 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocytosis 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1

Interventions

siltuximab 1 ruxolitinib 1 pelcitoclax 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Ascentage Pharma Group Inc.

Phase 1/2 Withdrawn

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡